Anthropic's Claude AI model has made its first biology discovery: a novel enzyme system that bears a resemblance to the mechanisms behind CRISPR, the revolutionary gene-editing technology. The finding was announced just days after Reuters revealed that Anthropic had quietly set up a wet lab in the San Francisco Bay Area, signaling the company's growing ambitions in life sciences and drug research beyond purely computational work.

Claude identified the system — now named array-associated reverse transcriptases, or ART — by sifting through large DNA databases. At its core is a reverse transcriptase (RT), an enzyme that converts RNA into DNA. What makes ART stand out is its repeating DNA sequences that mirror patterns seen in CRISPR systems, along with an additional protein of unknown function that Claude appears to be the first to flag.

Key Takeaways:

• While the underlying reverse transcriptase had been previously identified, Claude was the first to recognize the broader system's defining features, including its non-coding DNA array
• ART's CRISPR-like architecture could have implications for future gene-editing or molecular biology tools
• This discovery marks Anthropic's first published biology result, underscoring AI's expanding role in genomic research

Why it matters: This finding illustrates how AI can accelerate biological discovery — spotting patterns in massive genomic datasets that human researchers might miss. If ART's properties can be harnessed, it could open new doors in gene editing and molecular medicine.